Company logo

SCYX - SCYNEXIS, Inc.

NASDAQ -> Healthcare -> Drug Manufacturers—Specialty & Generic
Jersey City, United States

SCYX price evolution
SCYX
(in millions $) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Current assets
Cash $100.33 $112.72 $92.28 $93.31
Short term investments
Net receivables $0.03
Inventory $0.63 $0.09
Total current assets $103.93 $115.63 $95.38 $98.21
Long term investments
Property, plant & equipment $3.02 $3.12 $3.22 $3.3
Goodwill & intangible assets $1.15 $0.57 $0.38
Total noncurrent assets $5.95 $5.5 $4.7 $4.33
Total investments
Total assets $109.88 $121.13 $100.07 $102.54
Current liabilities
Accounts payable $7.51 $5.95 $6.52 $4.64
Deferred revenue
Short long term debt $0.07 $0.06 $0.06 $0.05
Total current liabilities $13.22 $19.88 $24.93 $26.4
Long term debt $42.65 $43.64 $15.44 $19.79
Total noncurrent liabilities $59.05 $68.93 $49.22 $53.38
Total debt $42.72 $43.7 $15.5 $19.84
Total liabilities $72.27 $88.81 $74.15 $79.78
Shareholders' equity
Retained earnings -$330.24 -$329.63 -$331.29 -$326.61
Other shareholder equity
Total shareholder equity $37.61 $32.32 $25.92 $22.76
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Current assets
Cash $93.31 $42.19 $11.77 $11.47
Short term investments $6.49 $32.72 $32.42
Net receivables
Inventory
Total current assets $98.21 $52.4 $51.46 $44.96
Long term investments
Property, plant & equipment $3.3 $3.6 $0.52 $0
Goodwill & intangible assets
Total noncurrent assets $4.33 $4.75 $1.71 $0.89
Total investments $6.49 $32.72 $32.42
Total assets $102.54 $57.15 $53.17 $45.85
Current liabilities
Accounts payable $4.64 $7.18 $3.65 $3.83
Deferred revenue $0.12 $0.38
Short long term debt $0.05 $0.04 $4.35
Total current liabilities $26.4 $11.01 $5.88 $10.14
Long term debt $19.79 $14.85 $15.08 $10.3
Total noncurrent liabilities $53.38 $33.24 $16.07 $14.3
Total debt $19.84 $14.88 $15.08 $14.65
Total liabilities $79.78 $44.26 $21.95 $24.44
Shareholders' equity
Retained earnings -$326.61 -$271.43 -$217.72 -$205.25
Other shareholder equity
Total shareholder equity $22.76 $12.89 $31.23 $21.41
(in millions $) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Revenue
Total revenue $0.52 $12.05
Cost of revenue $0.14
Gross Profit $0.37 $12.05
Operating activities
Research & development $4.4 $4.73 $6.95 $10.16
Selling, general & administrative $15.41 $12.77 $6.7 $5.18
Total operating expenses $19.81 $17.51 $13.64 $15.34
Operating income -$19.44 -$17.51 -$1.59 -$15.34
Income from continuing operations
EBIT $0.36 -$2.04 -$3.36 -$42.39
Income tax expense -$0.05 -$4.14 $1.1 -$0
Interest expense $1.02 $0.45 $0.21 $0.32
Net income
Net income -$0.6 $1.66 -$4.68 -$42.71
Income (for common shares) -$0.6 $1.66 -$4.68 -$42.71
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Revenue
Total revenue $0.12 $0.26 $0.26
Cost of revenue
Gross Profit $0.12 $0.26 $0.26
Operating activities
Research & development $36.52 $38.39 $21.56 $18.33
Selling, general & administrative $14.63 $10.65 $8.68 $8.25
Total operating expenses $51.15 $49.04 $30.24 $26.58
Operating income -$51.15 -$48.92 -$29.98 -$26.32
Income from continuing operations
EBIT -$57.15 -$52.72 -$17.58 -$23.61
Income tax expense -$3.15 -$6.74
Interest expense $1.18 $0.99 $1.63 $1.46
Net income
Net income -$55.19 -$53.71 -$12.47 -$25.06
Income (for common shares) -$55.19 -$53.71 -$12.47 -$25.06
(in millions $) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Net income -$0.6 $1.66 -$4.68 -$42.71
Operating activities
Depreciation $0.05 $0.06 $0.03 $0.03
Business acquisitions & disposals
Stock-based compensation $0.59 $0.54 $0.4 $1
Total cash flows from operations -$16.59 -$11.7 -$0.76 -$16.57
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.34 -$0.05 -$0.2 $6.47
Financing activities
Dividends paid
Sale and purchase of stock $4.61 $3.45 -$0.01 $85.72
Net borrowings $28.75
Total cash flows from financing $4.53 $32.18 -$0.07 $80.12
Effect of exchange rate
Change in cash and equivalents -$12.39 $20.43 -$1.03 $63.55
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Net income -$55.19 -$53.71 -$12.47 -$25.06
Operating activities
Depreciation $0.11 $0.11 $0.05 $0.04
Business acquisitions & disposals
Stock-based compensation $2.22 $1.83 $1.82 $1.66
Total cash flows from operations -$49.35 -$38.12 -$28.32 -$24.56
Investing activities
Capital expenditures -$0 -$0.56 -$0
Investments $6.48 $26.24 -$0.24 -$9.62
Total cash flows from investing $6.47 $26.24 -$0.8 -$9.62
Financing activities
Dividends paid
Sale and purchase of stock $90.37 $46.39 $31.7 $10.32
Net borrowings $9.51 -$1.23
Total cash flows from financing $94 $42.3 $29.42 $9.99
Effect of exchange rate
Change in cash and equivalents $51.12 $30.43 $0.3 -$24.19
Fundamentals
Market cap $152.80M
Enterprise value $95.19M
Shares outstanding 23.95M
Revenue $12.57M
EBITDA -$47.26M
EBIT -$47.43M
Net Income -$46.33M
Revenue Q/Q InfinityT%
Revenue Y/Y N/A
P/E ratio -3.30
EV/Sales 7.58
EV/EBITDA -2.01
EV/EBIT -2.01
P/S ratio 12.16
P/B ratio 4.06
Book/Share 1.57
Cash/Share 4.19
EPS -$1.93
ROA -42.74%
ROE -156.25%
Debt/Equity 3.51
Net debt/EBITDA 0.59
Current ratio 7.86
Quick ratio 7.81